The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products Administration (NMPA) giving the green light to CARsgen Therapeutics’ satri | The Claudin18.2-targeted therapy is the first CAR-T to win global approval in a solid tumor.

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products Administration (NMPA) giving the green light to CARsgen…